A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
Glioblastoma (GBM) is one of the most common primary and deadliest malignant brain tumor with chemoresistance and poor prognosis. There is a lack of effective chemotherapeutic drug for the treatment of GBM. In this work, we reported the preparation of a histone deacetylase (HDAC) inhibitor, DMC-HA,...
Guardado en:
Autores principales: | Hao Wang, Lei Shi, Zhimin Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2a623b45d799404f8abce9b4458c3db7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon N, et al.
Publicado: (2016) -
Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
por: Bingyi Zhou, et al.
Publicado: (2021) -
GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment
por: Han-Gyu Chang, et al.
Publicado: (2021) -
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <italic toggle="yes">Ex Vivo</italic> Lipopolysaccharide-Induced Inflammatory Responses
por: Christel Rothe Brinkmann, et al.
Publicado: (2018) -
Identification of the Histone Deacetylases Gene Family in Hemp Reveals Genes Regulating Cannabinoids Synthesis
por: Liu Yang, et al.
Publicado: (2021)